byiShook Opinion
Dec 18, 2024 - 22:45
Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech stock rocketed. The post Top-Notch Biotech Mesoblast Skyrockets 29% On Immune Condition Approval appeared first on Investor's Business Daily.
Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech stock rocketed.
The post Top-Notch Biotech Mesoblast Skyrockets 29% On Immune Condition Approval appeared first on Investor's Business Daily.